Bionano Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>BG</div>
BNGO -- USA Stock  

USD 9.15  0.72  8.54%

While this unique economic environment continues, Bionano Genomics may throw investors more surprises next month. We will evaluate why recent Bionano Genomics price moves suggest a bounce in February. Bionano Genomics is currently traded for 3.08. The entity stock is not elastic to its hype. The firm is forecasted to increase in value after the next press release, with the price going to jump to 3.18. The average volatility of headline impact on the company stock price is about 0.0%. The price upswing on the next news is estimated to be 3.25%, whereas the daily expected return is currently at 0.0%. Given the investment horizon of 30 days the next forecasted announcement will be in a few days.
Published over two weeks ago
View all stories for Bionano Genomics | View All Stories
Your bind date with Bionano Genomics
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Bionano Genomics has an asset utilization ratio of 39.36 percent. This suggests that the company is making $0.39 for each dollar of assets. An increasing asset utilization means that Bionano Genomics is more efficient with each dollar of assets it utilizes for everyday operations. The company recorded a loss per share of 0.52. Bionano Genomics had not issued any dividends in recent years.
The successful prediction of Bionano Genomics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Bionano Genomics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Bionano Genomics based on Bionano Genomics hews, social hype, general headline patterns, and widely used predictive technical indicators. We also calculate exposure to Bionano Genomics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Bionano Genomics's related companies.

Use Technical Analysis to project Bionano expected Price

Bionano Genomics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Bionano Genomics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Bionano Genomics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

How Bionano utilizes its cash?

To perform a cash flow analysis of Bionano Genomics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Bionano Genomics is receiving and how much cash it distributes out in a given period. The Bionano Genomics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Bionano Genomics Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (28.67 Million)

Acquisition by Chaubey Alka of 300000 shares of Bionano Genomics subject to Rule 16b-3

Legal trades by Bionano Genomics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Bionano insider trading alert for grant of stock option (right to buy) by Chaubey Alka, Chief Medical Officer, on 11th of October 2020. This event was filed by Bionano Genomics Inc with SEC on 2020-09-03. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down Bionano Genomics Indicators

Bionano Genomics reported the previous year's revenue of 7.3 M. Net Loss for the year was (37.28 M) with profit before overhead, payroll, taxes, and interest of 3.36 M.

Deferred Revenue Breakdown

Bionano Genomics Deferred Revenue yearly trend continues to be quite stable with very little volatility. Deferred Revenue may rise above about 345.9 K this year. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Bionano Genomics Deferred Revenue is quite stable at the moment as compared to the past year. The company's current value of Deferred Revenue is estimated at 345,924
2010
2017
2018
2019
2020
2021
2010691,653
2017354,626
2018270,998
2019358,000
2020322,200
2021345,924

Bionano Genomics implied volatility may change after the rise

Jensen alpha is down to 9.59. It may entail a possible volatility slide. Bionano Genomics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Bionano Genomics independently to ensure intended market timing strategies are aligned with expectations about Bionano Genomics volatility.

Our Takeaway on Bionano Genomics Investment

When is the right time to buy or sell Bionano Genomics? Buying stocks such as Bionano Genomics isn't very hard. However, what challenging for most investors is doing it at the right time. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities, deliver winning trades and diversify portfolios on a daily basis. To conclude, as of the 2nd of January 2021, our research shows that Bionano Genomics is a rather abnormally volatile investment opportunity with a below average probability of financial unrest in the next two years. From a slightly different view, the entity currently appears to be overvalued. However, our up-to-date 30 days Buy-Hold-Sell recommendation on the company is Strong Buy.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Bionano Genomics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com